In this Webinar, you will learn:
• How ex vivo drug response profiling can reveal genotype–drug response associations
• The feasibility and clinical impact of ex vivo drug response profiling for personalized treatment guidance in
hematologic malignancies
• Future potential application of ex vivo drug response profiling in precision medicine
About this Webinar:
Ex vivo drug response profiling has emerged as a promising tool for studying genotype–drug response associations, offering the potential for precision medicine, especially in cancer treatment. In this webinar, Peter-Martin Bruch will discuss the findings from the SMARTrial (NCT03488641), a prospective non-interventional trial that investigated the feasibility of ex vivo drug response profiling for guiding treatment decisions in hematologic malignancies. With a 91% of study results delivered within seven days, the trial highlighted the feasibility of this approach. More importantly, it showed in vivo therapy response beyond known genetic risk factors, demonstrating how functional profiling can enhance risk stratification and treatment personalization beyond traditional genetic markers.
Webinar certificate is available
About Peter-Martin Bruch and his group:
Peter-Martin Bruch is a physician scientist with a strong interest in unraveling resistance mechanisms in lymphoma. His research journey began in the Dietrich lab as a MD student in 2016 investigating the ex vivo effects of microenvironmental stimuli in chronic lymphocytic leukemia (CLL). He finished his medical studies in 2020 and continue his research work in parallel to his clinical duties in the hematology department. Currently, his main focus is using multiplexed immunofluorescence to characterize lymphoma biopsies. His group use both tumor cell intrinsic factors and microenvironmental composition to identify biomarkers of therapy response. His aim is to predict therapy response and the most effective treatment option for each individual patient.
His work aims to bring biology-based individualized treatment of lymphoma and leukemia into clinical practice. Working towards this goal, researchers from his team investigate biomarkers of response and therapy resistance using, among other techniques, functional profiling, multiparametric imaging and single-cell-sequencing. In parallel, they analyze clinically obtained data in their data warehouse projects to transfer clinical observations into meaningful guidelines.
For more information, please visit the research project pages or the lab’s website:
https://www.dietrichlab.de
Recent Publications:
[1] Schmitt L, et al. Cell Death Discov. 2024 Jun 11;10(1):279. [Content Brief]
[2] Brinkmann BJ, et al. Blood. 2024 Aug 15;144(7):784-789. [Content Brief]
[3] Roider T, et al. Nat Cell Biol. 2024 Mar;26(3):478-489. [Content Brief]
[4] Bruch PM, et al. Mol Syst Biol. 2022 Aug;18(8):e10855. [Content Brief]
[5] Bruch PM, et al. Leukemia. 2023 Feb;37(2):465-472. [Content Brief]